ABSTRACT
Objective To investigate the role of clinical pharmacists in identifying adverse drug reactions (ADR), to draw clinical attention to the possibility of drug-induced lung injury caused by rhG-CSF, and distinguish them from infectious diseases. Methods A case of rhG-CSF induced acute lung injury was analyzed. After analyzing the relationship between rhG-CSF and acute eosinophilic pneumonia, exploring the possible mechanism, in combination with the patient's condition, the clinical pharmacist put forward the suggestion for the treatment of the disease. Results After receiving rhG-CSF, the patient's eosinophils increased, the pneumonia was aggravated, and the effect of anti-infection treatment was poor. Eosinophils pneumonia associated with rhG-CSF was considered. The patient's pulmonary symptoms improved after treatment with glucocorticoid in combination with withdrawal of antibiotics and antiviral drugs, and eosinophil returned to normal. Conclusion rhG- can cause rare eosinophilic pneumonia. The clinical pharmacist's participation in clinical treatment can help to identify drug-induced diseases, reorient the direction of treatment and ensure the success of clinical therapy.
ABSTRACT
Objective To explore the role of pharmaceutical care in the treatment of patients with pulmonary infection secondary to suppurative thrombophlebitis. Methods The treatment of a patient diagnosed with pulmonary metastatic infection secondary to suppurative thrombophlebitis and the whole process of clinical pharmacists participating in the monitoring were analyzed retrospectively. The use of antibiotics was evaluated, and the experience of coagulation management in suppurative thrombophlebitis was explored. Results Based on the infection site, characteristics of septic thrombus, monitoring of vancomycin blood concentration, pharmacokinetics and pharmacodynamics characteristics of antibiotics, clinical pharmacists provided comprehensive pharmaceutical services for clinicians and patients in terms of anti-infection scheme adjustment, optimization of vancomycin individualized treatment, anticoagulant timing. Patient’s systemic infection and septic thrombus can be effectively controlled and which promotes the treatment of patients with suppurative thrombophlebitis. Conclusion Clinical pharmacists can play an important role in the treatment team of severe patients to improve the rational use of antibiotics.
ABSTRACT
Objective To establish a quality standard for Jianpibushen granules .Methods The five main ingredients of the formulation :Astragalus membranaceus ,Salvia miltiorrhiza Bunge ,Codonopsis pilosula ,Citrus reticulata Blanco and Paeonia lactif lora Pall ,were identified by thin layer chromatography (TLC) respectively .The content of peoniflorin in Paeo-nia lactif lora was determined by high performance liquid chromatography (HPLC) .The separation was performed on Agilent Eclipse Plus C18 column(4 .6 mm × 250 mm ,5 μm) .The mobile phase was acetonitrile and 0 .1% potassium dihydrogen phos-phate solution for gradient elution .The flow rate was 1 ml/min ,the column temperature was 25 ℃ ,the UV detection was per-formed at 230 nm .Results The spots in TLC were clear without interference in negative control .A good linear relationship was shown within the range of 8 .676-277 .632 μg /ml for peoniflorin (r=0 .999 9) .Conclusion This method is simple ,accu-rate and reproducible ,and can be used as an effective quality control of Jianpibushen granules .
ABSTRACT
OBJECTIVE:To investigate the role of clinical pharmacists in anti-infective treatment for the patient with septic shock. METHODS:Clinical pharmacists participated in anti-infective treatment for a patient with septic shock,assisted physicians to formulate individual regimen based on empirical anti-infective treatment,ESBLs producing Escherichia coli and anti-fungal treat-ment. Clinical pharmacists suggested using Itraconazole injection 200 mg,ivgtt,qd,for anti-fungal treatment;Itraconazole cap-sules 200 mg,po,bid,instead of fusidinic for anti-fungal treatment;meropenem 0.5 g,ivgtt,q6 h,for anti-infective treatment. RESULTS:Physicians adopted the suggestion of clinical pharmacists;the infection had been controlled after 16 d treatment and then the patient discharged from the hospital. CONCLUSIONS:Clinical pharmacists participate in clinical treatment,and assist phy-sicians to make a decision and formulate individual regimen,so as to promote rational drug use.
ABSTRACT
Objective To construct a gene delivery carrier with aptamer-polyethylene glycol-dendrimer-polyamidoamine (APT-PEG-PAMAM) ,forming nanoparticles to specifically target prostate cancer cell lines ,carrying prostate cancer cell pro-liferative suppressor microRNA :miRNA-34a .We investigated the transfection efficiency of this gene delivery system as well as functionally studied its inhibitory effect on prostate cancer (PCa) cell proliferation .Methods The construction of APT-PEG-PAMAM gene carrier was identified and confirmed by nuclear magnetic resonance (NMR) .The nano-complex sizes and zeta potential of APT-PEG-PAMAM gene carrier complexes were measured by zeta sizer .The efficiency of gene transfection of APT-PEG-PAMAM /miRNA nano-complexes were investigated by measuring the expression miRNA-34a in prostate cancer cells (PC3 and LNCaP);the PCa specific cell proliferation inhibition of APT-PEG-PAMAM / miRNA-34a nano-complexes were investigated by measuring CCK-8 cell proliferation inhibition experiments by comparing with APT-PEG-PAMAM and APT-PEG-PAMAM /miRNA-34a nano-complexes .Results NMR results demonstrated that APT-PEG-PAMAM /miRNA-34a nano-complexes were successfully synthesized by structural identification .Qualitative and quantitative transfection efficien-cy experiments data show that the cellular uptake of vectors were concentration-dependent ,after the APT further modified it significantly and increased the LNCaP cell transfection efficiency and specificity of PCa cells targeting ability .CCK8 cell prolif-eration assay data indicated that APT-PEG-PAMAM/miRNA-34a has the anti-PCa cells effect .Conclusion APT-PEG-PAM-AM/miRNA-34a may prove to see its efficacy for near future in pre-clinical and clinical study on the treatment of PCa .